KEY TAKEAWAYS
- The phase 1/2 study reported the longer-term follow-up of triple immunotherapy in platinum-resistant ovarian cancer.
- The main goals were assessing safety and tolerability, with a secondary focus on preliminary antitumor activity.
- Ongoing durable partial responses were noted with COM701 + BMS-986207 + nivolumab in heavily treated PROC patients.
Patients facing platinum-resistant ovarian cancer (PROC) encounter limited treatment options. Previous studies have highlighted promising outcomes with COM701 +/- BMS986207 + nivolumab. The novel triple immunotherapy sustained durable responses in PROC patients by targeting the DNAM-1 axis.
In a recent trial, 20 patients diagnosed with PROC were treated with COM701 at 20 mg/kg, BMS-986207 at 480 mg, and nivolumab at 480 mg intravenously every 4 weeks. The primary focus was assessing safety and tolerability, while secondary objectives included evaluating preliminary antitumor activity.
To be eligible, patients had to be at least 18 years old, have confirmed advanced malignancies, and have exhausted all available standard treatments. Those who had previously received inhibitors targeting PVRIG, TIGIT, or PD-(L)-1 were excluded. The responses were evaluated by investigators using RECIST v1.1, while safety assessments were conducted based on CTCAE v5.0 criteria.
As per a recent assessment, no new safety concerns emerged, indicating good tolerance for the combined treatment. Among the 20 patients involved, 4 (20%) achieved confirmed partial responses (PR), while 5 showed stable disease (SD), resulting in a Disease Control Rate (DCR) of 45% (comprising CR+PR+SD). However, no complete responses (CR) were observed.
The median age of patients was 61 years, and they had received a median of 4 prior lines of therapy, ranging from 1 to 10. The histology of patients achieving PR included 3 with high-grade serous adenocarcinoma and 1 with clear cell histology. A total of 3 patients remained on the study treatment for 449, 428, and 477 days, while 1 patient with high-grade serous adenocarcinoma stayed on the treatment for 222 days.
Sustained and durable confirmed partial responses persisted through continued treatment, achieved by blocking the DNAM-1 axis using the combination of COM701 + BMS-986207 + nivolumab in patients with heavily pre-treated PROC.
Source: https://jitc.bmj.com/content/11/Suppl_1/A758
Clinical Trial: https://clinicaltrials.gov/study/NCT04570839
Gaillard S, Sharma M, Vaena D, et al669 Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancerJournal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0669.
